Stock ACOG ALPHA COGNITION INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Alpha Cognition Inc. Toronto S.E.

Equities

ACOG

CA02074J2048

Biotechnology & Medical Research

End-of-day quote Toronto S.E.
Other stock markets
 		5-day change 1st Jan Change
- CAD -.--% Intraday chart for Alpha Cognition Inc. -.--% -.--%
Apr. 04 Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period MT
Apr. 04 Alpha Cognition Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

Managers

Managers TitleAgeSince
Denis G. Kay FOU
 Founder - 99-12-31
Michael McFadden CEO
 Chief Executive Officer 57 21-04-11
Ken Cawkell FOU
 Founder 72 19-12-31
Donald Kalkofen DFI
 Director of Finance/CFO 60 22-04-11
Lauren DAngelo COO
 Chief Operating Officer - 21-05-03

Members of the board

Members of the board TitleAgeSince
Ken Cawkell FOU
 Founder 72 19-12-31
Rajeev Bakshi BRD
 Director/Board Member 64 21-03-21
Michael McFadden CEO
 Chief Executive Officer 57 21-04-11
Len Mertz CHM
 Chairman - 21-03-21
Phillip Mertz BRD
 Director/Board Member - 21-03-21
John Havens BRD
 Director/Board Member - 21-03-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 149,925,536 127,560,415 ( 85.08 %) 0 85.08 %
Stock B 0 7,916,380 0 0

Shareholders

NameEquities%Valuation
John Havens
7.644 %
6,723,121 7.644 % 4 M $
Len Mertz
6.354 %
5,588,134 6.354 % 3 M $
Ken Cawkell
6.210 %
5,461,899 6.210 % 3 M $
Phillip Mertz
1.428 %
1,255,822 1.428 % 728 377 $
Donald Kalkofen
0.4178 %
367,500 0.4178 % 213 150 $
Michael McFadden
0.3279 %
288,348 0.3279 % 167 242 $

Company contact information

Alpha Cognition, Inc.

750 West Pender Street Suite 1200

V6C 2T8, Vancouver

+

http://www.alphacognition.com
address Alpha Cognition Inc.(ACOG)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.65 CAD
Average target price
1 CAD
Spread / Average Target
+53.85%
Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACOG Stock
  4. ACOG Stock
  5. Company Alpha Cognition Inc.